Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gary E Pakes
Fosamprenavir or Atazanavir Once Daily Boosted With Ritonavir 100mg, Plus Tenofovir/Emtricitabine, for the Initial Treatment of HIV Infection: 48-Week Results of ALERT
AIDS Research and Therapy
Virology
Molecular Medicine
Pharmacology
Related publications
Cost-Effectiveness Analysis of Tenofovir/Emtricitabine and Abacavir/Lamivudine in Combination With Efavirenz or Atazanavir/Ritonavir for Treatment-Naive Adults With Hiv-1 Infection in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study
Antiviral Therapy
Infectious Diseases
Pharmacology
First-Line Antiretroviral Therapy With Efavirenz Plus Tenofovir Disiproxil Fumarate/Emtricitabine or Rilpivirine Plus Tenofovir Disiproxil Fumarate/Emtricitabine: A Durability Comparison
HIV Medicine
Health Policy
Infectious Diseases
Pharmacology
Abacavir–Lamivudine Versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
New England Journal of Medicine
Medicine
Maraviroc 150 Mg Daily Plus Lopinavir/Ritonavir, a Nucleoside/Nucleotide Reverse Transcriptase Inhibitor-Sparing Regimen for HIV-infected Naive Patients: 48-Week Final Results of VEMAN Study
Clinical Microbiology and Infection
Medicine
Infectious Diseases
Microbiology
Resistance Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment-Naïve Patients Through 48 Weeks
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial
Journal of Acquired Immune Deficiency Syndromes
Infectious Diseases
Pharmacology
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir
AIDS Research and Human Retroviruses
Virology
Infectious Diseases
Immunology
Cost-Effectiveness of Atazanavir/Ritonavir Against Lopinavir/Ritonavir in the Treatment of People Living With Hiv in Peru
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental